Abstract
EMAP II (Endothelial Monocyte-Activating Polypeptide) – a new antiangiogenic proinflammatory cytokine that exhibits antitumor activity. In order to develop genetically engineered technology for EMAP II optimization of bacterial expression conditions within pET30a vector encoded EMAP II was carried out. Both the influence of target protein synthesis inductor IPTG concentration on its overall yield and optimal bacterial cultivation time before and after inductor addition were estimated. There was a proposed scheme for the cultivation of culture E. colі BL21(DE3)pLysE to achieve high yield of recombinant cytokine EMAP II at the level of 110 mg from 1 liter of bacterial culture.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
